Dr. Reddy`s rises on acquiring specialty brands Progynova, Cyclo-Progynova in India
Dr. Reddy's Laboratories is currently trading at Rs 1287.45, up by 6.60 points or 0.52% from its previous closing of Rs 1280.85 on the BSE.
The scrip opened at Rs 1292.70 and has touched a high and low of Rs 1297.00 and Rs 1282.90 respectively. So far 30056 shares were traded on the counter.
The BSE group 'A' stock of face value Rs 1 has touched a 52-week high of Rs 1377.95 on 12-Jun-2025 and a 52-week low of Rs 1025.90 on 07-Apr-2025.
Last one week high and low of the scrip stood at Rs 1297.00 and Rs 1258.80 respectively. The current market cap of the company is Rs 107163.99 crore.
The promoters holding in the company stood at 26.64%, while Institutions and Non-Institutions held 52.78% and 9.72% respectively.
Dr. Reddy's Laboratories has acquired the trademarks of specialty brands, Progynova and Cyclo-Progynova and related assets, for India from Mercury Pharma Group, a UK-headquartered specialty pharmaceutical company.
Progynova (estradiol valerate) is an oral hormone replacement therapy indicated for the treatment of estrogen deficiency symptoms and for the prevention of postmenopausal osteoporosis. Cyclo-Progynova (estradiol valerate and norgestrel) is a combined hormone replacement therapy indicated for the treatment of estrogen deficiency symptoms, providing both estrogen and progestogen components. As per IQVIA MAT December 2025, the brand recorded sales of Rs 100 crore. The acquisition strengthens Dr. Reddy’s gynaecology portfolio and marks a strategic entry into the hormone replacement therapy segment.
